|Contributor / Partner
Strategy published on : 06/10/2021 | 02:54
Entry price : 39.66$
Target : 49.9$
Stop-loss : 32.6$
Potential : 25.82%
The medium term support area around 38.84 USD should allow Halozyme Therapeutics, Inc. shares to re-establish an upward trend in the short term.
Investors have an opportunity to buy the stock and target the $ 49.9.
● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● For a short-term investment strategy, the company has poor fundamentals.
● According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
● The group's activity appears highly profitable thanks to its outperforming net margins.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
● Based on current prices, the company has particularly high valuation levels.
● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.